Sofinnova

Bioamber is a renewable chemistry company spun off from the US biotech company DNP Inc, and developping bio sourced molecules as alternatives to petroleum feedstock derived molecules for the chemical industry.

Percutaneous aortic valve replacement is a technology breakthrough for patients who will need only a few days of hospitalisation.

PregLem is a Swiss based specialty biopharmaceutical company dedicated to the development and commercialisation of innovative drugs for women’s reproductive medicine.

Omthera Pharmaceuticals is a cardiovascular specialty company developing a best in class Omega-3 pharmaceutical product called Epanova for the treatment of elevated triglyceredemia. Omthera owns a worldwide exclusive licence to Epanova.

Diallertest® Milk is becoming the standard of diagnostic for young children milk allergy. DBV is developping this VIASKIN® technology to diagnose and treat other allergies like peanuts…

Nanobodies®, derived from natural single chain antibodies in Camelides, will be the next generation therapeutic antibodies. The anti-TNFalpha is the first under clinical investigation.

Producing glyconjugates in a single step is the challenge GlycoVaxyn is facing in order to get vaccins cheaper and easier to produce.

Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries.

Movetis is a spin-off from Johnson & Johnson devoted to the development of drugs targeting gastrointestinal diseases.

Alosteric modulation of m-gluR receptors is on the forefront of innovations for new CNS drugs and specifically for anxiety, depression and schizophrénia.